Merck to Apply its Industry-Leading Vaccine Development Capabilities to SARS-CoV-2 Vaccine Program Originated by Themis…
Continue Reading-
NeuroVive makes a MSEK 20 directed share issue to leading Nordic life science investor Hadean Ventures
NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (”NeuroVive” or the ”Company”) has today decided upon a…
Continue Reading -
Themis and Institut Pasteur Join Coronavirus Vaccine Hunt
The Austrian biotech Themis — specializing in vaccines for infectious and insect-borne diseases — has…
Continue Reading -
Hadean Ventures receives Rising Star Award at the 10th edition of the Private Equity Exchange & Awards 2019 in Paris
Paris – Today Hadean Ventures won the Rising Star Award at the 10th edition of…
Continue Reading -
Hadean Ventures invests in Themis Bioscience GmbH EUR 40m Series D Financing round
Hadean Ventures invests in Themis Bioscience GmbH EUR 40m Series D Financing round Investment Q2…
Continue Reading -
Hadean Ventures leads 40 million SEK (€3.7 million) investment round into SAGA to advance ultrasensitive cancer liquid biopsies
LUND, Sweden and OSLO, Norway, June 11, 2019 — /B3C Newswire/ — SAGA Diagnostics AB,…
Continue Reading -
Hadean Ventures’ Ingrid Teigland Akay receives Investor of the Year award at the SHE conference
Oslo 6th March, 2019. Today Ingrid Teigland Akay, founder and managing partner at Hadean Ventures,…
Continue Reading
